Novo Nordisk's Wegovy HD Approved with 20.7% Weight Loss

The U.S. FDA has approved Wegovy® HD (semaglutide 7.2 mg), an injectable medication administered once weekly, for reducing excess body weight and maintaining long-term weight reduction. Clinical data indicates an average weight loss of 20.7% among participants. This approval offers a new, higher-dose option for patients seeking effective weight management solutions, reinforcing Novo Nordisk's position in the obesity treatment market and providing a significant advancement for therapeutic interventions.